181 related articles for article (PubMed ID: 27733938)
1. Serum Soluble CD163 and its association with various disease parameters in patients with systemic sclerosis.
Hassan WA; Baraka EA; Elnady BM; Gouda TM; Fouad N
Eur J Rheumatol; 2016 Sep; 3(3):95-100. PubMed ID: 27733938
[TBL] [Abstract][Full Text] [Related]
2. High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis.
Kowal-Bielecka O; Bielecki M; Guiducci S; Trzcinska-Butkiewicz B; Michalska-Jakubus M; Matucci-Cerinic M; Brzosko M; Krasowska D; Chyczewski L; Kowal K
Arthritis Res Ther; 2013; 15(3):R69. PubMed ID: 23800379
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of soluble CD163 in patients with systemic sclerosis.
Nakayama W; Jinnin M; Makino K; Kajihara I; Makino T; Fukushima S; Inoue Y; Ihn H
Rheumatol Int; 2012 Feb; 32(2):403-7. PubMed ID: 21120485
[TBL] [Abstract][Full Text] [Related]
4. Increased serum levels of soluble CD163 in patients with scleroderma.
Shimizu K; Ogawa F; Yoshizaki A; Akiyama Y; Kuwatsuka Y; Okazaki S; Tomita H; Takenaka M; Sato S
Clin Rheumatol; 2012 Jul; 31(7):1059-64. PubMed ID: 22453843
[TBL] [Abstract][Full Text] [Related]
5. Increased release of soluble CD163 by the peripheral blood mononuclear cells is associated with worse prognosis in patients with systemic sclerosis.
Bielecki M; Kowal K; Lapinska A; Chyczewski L; Kowal-Bielecka O
Adv Med Sci; 2013; 58(1):126-33. PubMed ID: 23640944
[TBL] [Abstract][Full Text] [Related]
6. Soluble CD163 as a Potential Biomarker in Systemic Sclerosis.
Frantz C; Pezet S; Avouac J; Allanore Y
Dis Markers; 2018; 2018():8509583. PubMed ID: 29805720
[TBL] [Abstract][Full Text] [Related]
7. CD163 expression is increased in the involved skin and sera of patients with systemic lupus erythematosus.
Nakayama W; Jinnin M; Makino K; Kajihara I; Makino T; Fukushima S; Sakai K; Inoue Y; Ihn H
Eur J Dermatol; 2012; 22(4):512-7. PubMed ID: 22576016
[TBL] [Abstract][Full Text] [Related]
8. Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue.
Peng QL; Zhang YL; Shu XM; Yang HB; Zhang L; Chen F; Lu X; Wang GC
J Rheumatol; 2015 Jun; 42(6):979-87. PubMed ID: 25877505
[TBL] [Abstract][Full Text] [Related]
9. Expression of soluble sCD163 in serum of psoriatic patients is modulated by Goeckerman therapy.
Kondelkova K; Krejsek J; Borska L; Fiala Z; Hamakova K; Andrys C
Allergol Immunopathol (Madr); 2013; 41(3):158-62. PubMed ID: 22765877
[TBL] [Abstract][Full Text] [Related]
10. Serum-Soluble CD163 Levels as a Prognostic Biomarker in Patients with Diffuse Large B-Cell Lymphoma Treated with Chemoimmunotherapy.
Koudouna A; Gkioka AI; Gkiokas A; Tryfou TM; Papadatou M; Alexandropoulos A; Bartzi V; Kafasi N; Kyrtsonis MC
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474108
[TBL] [Abstract][Full Text] [Related]
11. Soluble CD163 in young sickle cell disease patients and their trait siblings: a biomarker for pulmonary hypertension and vaso-occlusive complications.
Tantawy AA; Adly AA; Ismail EA
Blood Coagul Fibrinolysis; 2012 Oct; 23(7):640-8. PubMed ID: 22885767
[TBL] [Abstract][Full Text] [Related]
12. Soluble macrophage-derived CD163: a homogenous ectodomain protein with a dissociable haptoglobin-hemoglobin binding.
Møller HJ; Nielsen MJ; Maniecki MB; Madsen M; Moestrup SK
Immunobiology; 2010 May; 215(5):406-12. PubMed ID: 19581020
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of soluble CD163 as a specific marker of macrophage/monocyte activity in sarcoidosis patients.
Tanimura H; Mizuno K; Okamoto H
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Jul; 32(2):99-105. PubMed ID: 26278688
[TBL] [Abstract][Full Text] [Related]
14. Serum Calponin 3 Levels in Patients with Systemic Sclerosis: Possible Association with Skin Sclerosis and Arthralgia.
Kotani H; Yoshizaki A; Matsuda KM; Norimatsu Y; Kuzumi A; Fukayama M; Fukasawa T; Ebata S; Yoshizaki-Ogawa A; Asano Y; Oba K; Sato S
J Clin Med; 2021 Jan; 10(2):. PubMed ID: 33466615
[TBL] [Abstract][Full Text] [Related]
15. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.
Sugaya M; Miyagaki T; Ohmatsu H; Suga H; Kai H; Kamata M; Fujita H; Asano Y; Tada Y; Kadono T; Okochi H; Sato S
J Dermatol Sci; 2012 Oct; 68(1):45-51. PubMed ID: 22884782
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis.
Taniguchi T; Asano Y; Akamata K; Noda S; Masui Y; Yamada D; Takahashi T; Ichimura Y; Toyama T; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
J Rheumatol; 2012 Mar; 39(3):539-44. PubMed ID: 22247367
[TBL] [Abstract][Full Text] [Related]
17. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
[TBL] [Abstract][Full Text] [Related]
18. Utility of Macrophage-activated Marker CD163 for Diagnosis and Prognosis in Pulmonary Tuberculosis.
Suzuki Y; Shirai M; Asada K; Miwa S; Karayama M; Nakamura Y; Inui N; Shirai T; Hayakawa H; Baba S; Suda T
Ann Am Thorac Soc; 2017 Jan; 14(1):57-64. PubMed ID: 27684274
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.
Enomoto Y; Suzuki Y; Hozumi H; Mori K; Kono M; Karayama M; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suzuki D; Ogawa N; Nakashima R; Mimori T; Iwashita T; Suda T
Arthritis Res Ther; 2017 Jan; 19(1):9. PubMed ID: 28103926
[TBL] [Abstract][Full Text] [Related]
20. Soluble CD163.
Møller HJ
Scand J Clin Lab Invest; 2012 Feb; 72(1):1-13. PubMed ID: 22060747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
